Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03950609 · ClinicalTrials.gov registry record · Phase 2
Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
A Phase 2 study of Neuroendocrine Neoplasm and Advanced Carcinoid Tumor, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT03950609: Active Phase 2 study of Neuroendocrine Neoplasm and Advanced Carcinoid Tumor, sponsored by M.D. Anderson Cancer Center.
NCT03950609 is a Phase 2 study of Neuroendocrine Neoplasm and Advanced Carcinoid Tumor that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 36 participants, below the 126-participant average among 6 other Neuroendocrine Neoplasm trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03950609, a Phase 2 study of Neuroendocrine Neoplasm and Advanced Carcinoid Tumor, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well lenvatinib and everolimus work in treating patients with carcinoid tumors that have spread to other places in the body (advanced) and cannot be removed by surgery (unresectable). Lenvatinib and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
Graded with Response Evaluation Criteria in Solid Tumors version 1.1
Conditions Studied
Interventions
- DRUG Everolimus
- DRUG Lenvatinib
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2019-07-30 |
| Est. Completion | 2028-03-30 |
| Phase | Phase 2 |
What the registry record for NCT03950609 still lists
NCT03950609 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 126-participant average among 6 other Neuroendocrine Neoplasm trials with a reported enrollment target (71% lower).
The record links to 5 conditions, with Neuroendocrine Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Everolimus is the first listed.
NCT03950609 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03950609 about?
NCT03950609 is a clinical study titled "Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors". This phase II trial studies how well lenvatinib and everolimus work in treating patients with carcinoid tumors that have spread to other places in the body (advanced) and cannot be removed by surgery (unresectable). Lenvatinib and everolimus may stop the growth of tumor cells by blocking some of the...
What is the current status of trial NCT03950609?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2019-07-30. Estimated completion is 2028-03-30.
What conditions does trial NCT03950609 study?
This clinical trial studies the following conditions: Neuroendocrine Neoplasm, Advanced Carcinoid Tumor, Digestive System Neuroendocrine Neoplasm, Multiple Endocrine Neoplasia, Type 1, Unresectable Carcinoid Tumor.
What interventions are being tested in trial NCT03950609?
The interventions under investigation include: Everolimus (DRUG), Lenvatinib (DRUG).
Who is sponsoring clinical trial NCT03950609?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03950609 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases
ACTIVE NOT RECRUITING · Phase 2
-
Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
COMPLETED · Phase 2
-
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
RECRUITING · Phase 1
-
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
ACTIVE NOT RECRUITING · Phase 3
-
Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI